Company intelligence / Profile preview
Eusol Biotech Co., Ltd.
Taipei, Taiwanen.eusol-biotech.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Eusol Biotech has conducted Phase 3 clinical trials for ES135 (rhFGF1) for spinal cord injury and SM-1 (a 3-in-1 combination sleeping aid). The company has tested ES135 in approximately 300 patients across Phase 1, 2, and 3 trials. Currently, ES135 is being tested in an exploratory clinical trial for carpal tunnel syndrome.
- Therapeutic areas
- PsychiatryCardiovascularDermatologyNeurologyInfectious Diseases
- Modalities
- Protein drugs (recombinant human acid fibroblast growth factor)small molecule drugscombination drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Eusol Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eusol Biotech Co., Ltd..